Showing 8,241 - 8,260 results of 34,954 for search '(( 50 ((we decrease) OR (((nn decrease) OR (a decrease)))) ) OR ( 5 point decrease ))', query time: 1.29s Refine Results
  1. 8241
  2. 8242

    Data_Sheet_5_Bacteroides abundance drives birth mode dependent infant gut microbiota developmental trajectories.XLSX by Dollwin Matharu (13914927)

    Published 2022
    “…Background and aims<p>Birth mode and other early life factors affect a newborn's microbial colonization with potential long-term health effects. …”
  3. 8243
  4. 8244
  5. 8245

    PCAIs inhibit NCI-H23 cell line viability. by Matthew D. Gregory (19929096)

    Published 2024
    “…Polyisoprenylated Cysteinyl amide Inhibitors (PCAIs) constitute a group of potential cancer therapy agents that we designed to specifically disrupt and suppress hyperactive G-protein signaling, such as that caused by mutated RAS proteins. …”
  6. 8246

    PCAIs disrupt actin filaments in NCI-H23 cells. by Matthew D. Gregory (19929096)

    Published 2024
    “…Polyisoprenylated Cysteinyl amide Inhibitors (PCAIs) constitute a group of potential cancer therapy agents that we designed to specifically disrupt and suppress hyperactive G-protein signaling, such as that caused by mutated RAS proteins. …”
  7. 8247

    PCAIs suppress 3D NCI-H23 cell invasion. by Matthew D. Gregory (19929096)

    Published 2024
    “…Polyisoprenylated Cysteinyl amide Inhibitors (PCAIs) constitute a group of potential cancer therapy agents that we designed to specifically disrupt and suppress hyperactive G-protein signaling, such as that caused by mutated RAS proteins. …”
  8. 8248

    PCAIs suppress NCI-H23 cancer cell migration. by Matthew D. Gregory (19929096)

    Published 2024
    “…Polyisoprenylated Cysteinyl amide Inhibitors (PCAIs) constitute a group of potential cancer therapy agents that we designed to specifically disrupt and suppress hyperactive G-protein signaling, such as that caused by mutated RAS proteins. …”
  9. 8249

    PCAIs induce apoptosis in NCI-H23 cells. by Matthew D. Gregory (19929096)

    Published 2024
    “…Polyisoprenylated Cysteinyl amide Inhibitors (PCAIs) constitute a group of potential cancer therapy agents that we designed to specifically disrupt and suppress hyperactive G-protein signaling, such as that caused by mutated RAS proteins. …”
  10. 8250
  11. 8251
  12. 8252
  13. 8253

    DNMT1 reduces cisplatin sensitivity partially through downregulating FOXO3a in ovarian cancer cells by Chong Guo (5819105)

    Published 2025
    “…Knocking down of DNMT1 could decrease the IC<sub>50</sub> of cisplatin. Treatment with cisplatin may reduce FOXO3a expression in OC cells. …”
  14. 8254
  15. 8255

    A randomized controlled trial of a combination of antiviral and nonsteroidal anti-inflammatory treatment in a bovine model of respiratory syncytial virus infection by Paul Walsh (662015)

    Published 2020
    “…This benefit was greater when treatment was initiated at 3 days rather than 5 days post infection with decreased clinical scores and lower respiratory rates at both time points. …”
  16. 8256
  17. 8257
  18. 8258
  19. 8259

    Suppression by extracellular QRNA from TNP Ts Sup free of exosomes, or miR-150 alone, associating with B-cell derived Ag-specific exosomes from the assayed CS-effector cell mixture... by Krzysztof Bryniarski (731989)

    Published 2015
    “…</b></u> Similarly, two day immune B-1 B cell-derived exosomes, supplemented with decreasing doses of miR-150 alone, mediated suppression of TNP-CS-effector cell adoptive transfer (Groups E-G), down to a dose of 750pg per eventual recipient, which is 50 femtomoles per eventual recipient (Group G). …”
  20. 8260